Cell Source, Inc. market cap history
Cell Source, Inc.'s market value at each date on file, Jan 1, 2020 to Dec 25, 2022, with its rank among the world's companies and the source of each value.
The short answer
Cell Source, Inc.'s market capitalisation was $20 M on Dec 25, 2022.
No newer market value of Cell Source, Inc. is on file: no market-data feed is connected for its exchange yet.
From $29 M on Jan 1, 2020, its market value changed by -31.0% to $20 M on Dec 25, 2022, -11.7% a year.
The highest value on record is $64 M on Jan 1, 2021; the lowest, $20 M on Dec 25, 2022.
Newest figure: Dec 25, 2022.
-11.7% a year from the first value to the newest (compound growth).
Market cap and world rank by date
The world rank compares every company valued on the same date; dates in between are not ranked.
| Date | Market cap | Change since the row before | World rank | Rank in USA | Source |
|---|---|---|---|---|---|
| Dec 25, 2022 | $20 M | -47.4% | #29,358 | #5,282 | value.today snapshot |
| Jan 7, 2022 | $38 M | -40.6% | #27,619 | #5,048 | value.today snapshot |
| Jan 1, 2021 | $64 M | +120.7% | #19,823 | #3,942 | value.today snapshot |
| Jan 1, 2020 | $29 M | — | #23,874 | #4,355 | value.today snapshot |
Questions and answers#
What is Cell Source, Inc.'s market cap?
Cell Source, Inc.'s market capitalisation was $20 M on Dec 25, 2022. No newer market value of Cell Source, Inc. is on file: no market-data feed is connected for its exchange yet.
How has Cell Source, Inc.'s market cap changed over time?
From $29 M on Jan 1, 2020, its market value changed by -31.0% to $20 M on Dec 25, 2022, -11.7% a year.
When was Cell Source, Inc. worth the most?
Of the values on file, its highest market cap was $64 M on Jan 1, 2021.
What was Cell Source, Inc.'s market cap in 2021?
$64 M on Jan 1, 2021, #19,823 in the world.
What was Cell Source, Inc.'s market cap in 2020?
$29 M on Jan 1, 2020, #23,874 in the world.
More about Cell Source, Inc.#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B